Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 5/20 | 0.69 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.63 |
| ▸ | LNPEP | Q9UIQ6 | 6/20 | 0.62 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.61 |
| ▸ | ANPEP | P15144 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29532971 | 0.92 | REN (0.67) | RENAGTR1LNPEPAGTR2 | |
| SCHEMBL31332308 | 0.88 | REN (0.64) | RENAGTR1LNPEPAGTR2ANPEP | |
| SCHEMBL29657514 | 0.83 | REN (0.78) | RENAGTR1AGTR2 | |
| SCHEMBL15336163 | 0.83 | AGTR1 (0.71) | RENAGTR1LNPEPAGTR2ANPEP | |
| Angiotensin Iv SCHEMBL10066237 | 0.82 | LNPEP (0.82) | RENAGTR1LNPEPAGTR2ANPEP | |
| Angiotensin Iv SCHEMBL27169570 | 0.82 | LNPEP (0.82) | RENAGTR1LNPEPAGTR2ANPEP | |
| SCHEMBL29440860 | 0.82 | SLC6A2 (0.62) | — | |
| SCHEMBL29843115 | 0.82 | REN (0.58) | RENAGTR1LNPEPAGTR2 | |
| SCHEMBL29463333 | 0.81 | AGTR2 (0.89) | RENAGTR1AGTR2 | |
| Saralasin SCHEMBL24 | 0.81 | AGTR1 (0.82) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | REN 580/4885AGTR1 51/4885LNPEP 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.